Immunology offers an unprecedented opportunity for the science-driven development of
therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and
blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene
discovery to patient benefit, have created a paradigm for driving such endeavors.